FDA
-
-
-
-
-
-
-
TROPION-Urothelial04 Phase 3 Trial of Datroway® Initiated as Adjuvant Therapy in Patients with High-Risk Muscle Invasive Urothelial Cancer
-
-
-
-
-
-
-
AstraZeneca unit receives FDA priority review for rare kidney disease treatment
-
-
-
-
-
-
-
FDA Approves Durvalumab in Combination with Bacillus Calmette-Guerin for High-Risk Non-Muscle Invasive Bladder Cancer
-
-
-
-
-
-
-
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors
-
-
-
-
-
-
-
Enhertu® Approved in the U.S. for Two New Indications for Patients with HER2 Positive Early Breast Cancer
-
-
-
-
-
-
-
BREZTRI approved in the US for asthma as first and only triple therapy for patients 12 years of age and older
-
-
-
-
-
-
-
Advancements in Novel Immunotherapeutics in The Oncology Battle
-
329,928 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

